2018 AHA/ACC 血胆固醇管理指南系统评价:非他汀类调脂药物的证据
该系统评价评估在他汀基础上加用非他汀类调脂药物对已知ASCVD或高危患者的获益与危害,纳入10项样本量>1000例、随访>1年的随机对照试验。结果显示依折麦布和PCSK9抑制剂可减少ASCVD事件,而烟酸和胆固醇酯转移蛋白抑制剂无获益证据。
要点
- 依折麦布联合辛伐他汀较辛伐他汀单药降低主要复合终点1.8%(7年NNT=56)。
- evolocumab降低主要终点1.5%(2.2年NNT=67),alirocumab降低1.6%(2.8年NNT=63)。
- 烟酸或胆固醇酯转移蛋白抑制剂加用他汀未见ASCVD获益证据。
核心结论
- 在他汀基础上加用依折麦布或PCSK9抑制剂有减少ASCVD事件的证据,而烟酸或胆固醇酯转移蛋白抑制剂无获益证据。
研究设计与样本
- 系统评价纳入10项随机对照试验,样本量>1000例且设计随访>1年,评估非他汀类调脂药物对比他汀单药在已知ASCVD或高危人群中的获益与危害。
主要发现
- IMPROVE-IT中依折麦布/辛伐他汀对比辛伐他汀7年降低主要终点1.8%(HR 0.90,95%CI 0.84-0.96,7年NNT=56)。
- FOURIER中evolocumab 2.2年降低主要终点1.5%(HR 0.80,95%CI 0.73-0.88,2.2年NNT=67)。
- ODYSSEY OUTCOMES中alirocumab 2.8年降低主要终点1.6%(HR 0.86,95%CI 0.79-0.93,2.8年NNT=63)。
- 依折麦布和PCSK9抑制剂治疗组与对照组在肌肉骨骼、神经认知、胃肠道或其他不良事件风险上无差异。
- 烟酸加用他汀无获益证据;胆固醇酯转移蛋白抑制剂改善ASCVD风险或不良事件的证据极少。
临床怎么用
- 对已知ASCVD或高危患者,在他汀基础上可考虑加用依折麦布或PCSK9抑制剂以进一步降低ASCVD风险。
- 不推荐加用烟酸或胆固醇酯转移蛋白抑制剂用于降低ASCVD风险。
局限性
- 10项随机对照试验的样本量、随访时间和报告的主要终点存在显著差异,限制直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of blood cholesterol found little evidence to support the use of nonstatin lipid-modifying medications to reduce atherosclerotic cardiovascular disease (ASCVD) events. Since publication of these guidelines, multiple randomized controlled trials evaluating nonstatin lipid-modifying medications have been published. METHODS: We performed a systematic review to assess the magnitude of benefit and/or harm from additional lipid-modifying therapies compared with statins alone in individuals with known ASCVD or at high risk of ASCVD. We included data from randomized controlled trials with a sample size of >1,000 patients and designed for follow-up >1 year. We performed a comprehensive literature search and identified 10 randomized controlled trials for intensive review, including trials evaluating ezetimibe, niacin, cholesterol-ester transfer protein inhibitors, and PCSK9 inhibitors. The prespecified primary outcome for this review was a composite of fatal cardiovascular events, nonfatal myocardial infarction, and nonfatal stroke. RESULTS: The cardiovascular benefit of nonstatin lipid-modifying therapies varied significantly according to the class of medication. There was evidence for reduced ASCVD morbidity with ezetimibe and 2 PSCK9 inhibitors. Reduced ASCVD mortality rate was reported for 1 PCSK9 inhibitor. The use of ezetimibe/simvastatin versus simvastatin in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) reduced the primary outcome by 1.8% over 7 years (hazard ratio: 0.90; 95% CI: 0.84-0.96], 7-year number needed to treat: 56). The PSCK9 inhibitor evolocumab in the FOURIER study (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) decreased the primary outcome by 1.5% over 2.2 years (hazard ratio: 0.80; 95% CI: 0.73-0.88; 2.2=year number needed to treat: 67). In ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), alirocumab reduced the primary outcome by 1.6% over 2.8 years (hazard ratio: 0.86; 95% CI: 0.79-0.93; 2.8-year number needed to treat: 63). For ezetimibe and the PSCK9 inhibitors, rates of musculoskeletal, neurocognitive, gastrointestinal, or other adverse event risks did not differ between the treatment and control groups. For patients at high risk of ASCVD already on background statin therapy, there was minimal evidence for improved ASCVD risk or adverse events with cholesterol-ester transfer protein inhibitors. There was no evidence of benefit for the addition of niacin to statin therapy. Direct comparisons of the results of the 10 randomized controlled trials were limited by significant differences in sample size, duration of follow-up, and reported primary outcomes. CONCLUSIONS: In a systematic review of the evidence for adding nonstatin lipid-modifying therapies to statins to reduce ASCVD risk, we found evidence of benefit for ezetimibe and PCSK9 inhibitors but not for niacin or cholesterol-ester transfer protein inhibitors.
引用
- Wilson PWF, Polonsky TS, Miedema MD, et al. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018. PMID: 30423394. doi:10.1016/j.jacc.2018.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。